Urogen Pharma Ltd (URGN)

Mar 10, 2025, 11:44 AM EDT - 24 days ago

UroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 8:00 AM EDT - 24 days ago

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

Mar 7, 2025, 8:00 AM EST - 27 days ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2025, 8:00 AM EST - 5 weeks ago

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

Feb 24, 2025, 4:00 PM EST - 5 weeks ago

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 8:00 AM EST - 6 weeks ago

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

Feb 14, 2025, 2:30 PM EST - 6 weeks ago

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

Feb 12, 2025, 8:00 AM EST - 7 weeks ago

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

Jan 31, 2025, 10:42 AM EST - 2 months ago

UroGen: Upcoming PDUFA, Some Concerns Remain

Jan 30, 2025, 8:00 AM EST - 2 months ago

UroGen Pharma to Present at Upcoming Investor Conferences

Jan 22, 2025, 8:00 AM EST - 2 months ago

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

Jan 15, 2025, 8:00 AM EST - 2 months ago

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

Dec 5, 2024, 3:30 PM EST - 4 months ago

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

Dec 5, 2024, 3:15 PM EST - 4 months ago

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

Dec 2, 2024, 8:00 AM EST - 4 months ago

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

Nov 26, 2024, 8:00 AM EST - 4 months ago

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

Nov 16, 2024, 8:00 AM EST - 4 months ago

Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy +

ACB RPRX TALO CAAP CASY DLO EME

Nov 13, 2024, 8:02 AM EST - 5 months ago

UroGen Pharma: Choice Based On Near Term High Value PDUFA

Nov 6, 2024, 5:12 PM EST - 5 months ago

UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:00 AM EST - 5 months ago

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

Nov 5, 2024, 8:00 AM EST - 5 months ago

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 30, 2024, 8:00 AM EDT - 5 months ago

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

Oct 28, 2024, 8:00 AM EDT - 5 months ago

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Oct 15, 2024, 4:30 PM EDT - 6 months ago

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

Oct 9, 2024, 8:00 AM EDT - 6 months ago

UroGen Appoints Chris Degnan as Chief Financial Officer

Oct 2, 2024, 8:00 AM EDT - 6 months ago

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Sep 16, 2024, 8:00 AM EDT - 7 months ago

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

Aug 29, 2024, 9:35 AM EDT - 7 months ago

UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector

Aug 14, 2024, 8:00 AM EDT - 8 months ago

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Aug 13, 2024, 3:05 PM EDT - 8 months ago

UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 8:00 AM EDT - 8 months ago

UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

Aug 5, 2024, 8:00 AM EDT - 8 months ago

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Jun 17, 2024, 10:51 PM EDT - 10 months ago

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

Jun 17, 2024, 4:46 PM EDT - 10 months ago

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Jun 17, 2024, 9:00 AM EDT - 10 months ago

UroGen: Q3 NDA Opens Hefty Revenue Opportunity

Jun 13, 2024, 10:54 AM EDT - 10 months ago

Uber Advertising Announces Exclusive Partnership with T-Mobile Advertising Solutions

GDYN

Jun 13, 2024, 10:49 AM EDT - 10 months ago

AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100

Jun 13, 2024, 10:45 AM EDT - 10 months ago

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Jun 6, 2024, 8:00 AM EDT - 10 months ago

UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024

Jun 5, 2024, 8:00 AM EDT - 10 months ago

UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Jun 3, 2024, 8:00 AM EDT - 10 months ago

UroGen Pharma Appoints David Lin as New Chief Commercial Officer

May 22, 2024, 8:00 AM EDT - 11 months ago

UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit

May 13, 2024, 6:30 PM EDT - 11 months ago

UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript

May 13, 2024, 8:00 AM EDT - 11 months ago

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

May 7, 2024, 8:00 AM EDT - 11 months ago

UroGen Pharma to Participate at Upcoming Investor Conferences

May 5, 2024, 12:20 PM EDT - 11 months ago

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

May 4, 2024, 3:20 PM EDT - 11 months ago

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

May 4, 2024, 11:50 AM EDT - 11 months ago

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

May 3, 2024, 8:00 AM EDT - 11 months ago

UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

Apr 17, 2024, 12:02 PM EDT - 1 year ago

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers